European Commission approves Roche & #039;s Tecentriq SC, the EU & #039;s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)'s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news